Floatz logo

DACTOLISIB

Malignant PEComa (Perivascular Epithelioid Cell Tumors)

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Malignant PEComa (Perivascular Epithelioid Cell Tumors) cohort.

Asset / SponsorPhaseRating
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Ivocizumab
Fudan University
Phase 2NR

Same molecule, other indications

DACTOLISIB is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →